• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Everest Organics develops remdesivir API

expresspharmaAugust 11, 2020

Tag: Everest Organics , Remdesivir , API

Everest Organics has announced that it has successfully developed remdesivir API has been in its R&D facility.

Dr Sirisha Srikakarlapudi, Director, EOL – New Product Development said, “lt’s a moment of utmost satisfaction that with hard work of the past few months by Everest Organics R&D team, we have been able to successfully develop remdesivir API at lab scale in a short span of time. In fact, we are poised for the development of more products in the anti-viral segments in the future.”


Previous:IIT Mandi team compares disordered proteins in COVID-19 virus through computational studies

Next:VAV Lipids gets written confirmation from CDSCO for Ratnagiri facility

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Everest Organics develops remdesivir API | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

New machine for sale Rapid cool-down and heat-up Equipment SUNDI-725WN

New machine for sale Rapid cool-down and heat-up Equipment SUNDI-725WN
lanzapine Impurity 10

lanzapine Impurity 10
Pharmaceutical API powder packaging aluminum bottles

Pharmaceutical API powder packaging aluminum bottles
QUETIAPINE

QUETIAPINE
Ticagrelor Intermediate and API

Ticagrelor Intermediate and API
Mirtazapine

Mirtazapine
Oxytetracycline Hydrochloride API

Oxytetracycline Hydrochloride API
Rhoifolin (Apigenin 7-O-neohesperidoside)

Rhoifolin (Apigenin 7-O-neohesperidoside)
Apixaban

Apixaban
(-)-Syringaresnol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside

(-)-Syringaresnol-4-O-β-D-apiofuranosyl-(1→2)-β-D-glucopyranoside

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service